...
BMRNLARGE

BioMarin Pharmaceutical Inc.

HealthcareBiotechnology
$61.73
$0.01(+1.01%)
52W$50.76
$73.51
FinancialsValuationvs AGIO
Updated Mar 1, 12:00 AM
RSI57
RS Rating60/99
Beta0.74
Volatility35%
F-Score5/9
Mkt Cap$11.9B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

BioMarin Pharmaceutical Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 60), indicating performance broadly in line with the market. Earnings contraction of 134% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
60
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.74
vs S&P 500
DEFENSIVE
52W Position
48%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$58.66
50 SMA > 100 SMA$56.12
100 SMA > 150 SMA$56.31
150 SMA > 200 SMA$56.56

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$60.08+2.75%ABOVE
50 SMA$58.66+5.23%ABOVE
100 SMA$56.12+10.00%ABOVE
150 SMA$56.31+9.62%ABOVE
200 SMA$56.56+9.15%ABOVE

Price Performance

1D+1.0%
1W-1.9%
1M+8.9%
3M+10.4%
6M+7.0%
YTD+3.8%
1Y-13.3%
3Y-14.7%
52-Week Trading Range48% from low
$61.73
52W Low$50.76
52W High$73.51

Technical Indicators

RSI (14)NEUTRAL
56.6
305070
VCP ScoreWARM
6/10
Base depth: 24.9%

Risk Profile

Beta
0.74
52W Vol
35%
ATR
$2.48
Max DD (1Y)
-29%

Volume Analysis

Today
61
50D Avg
1.86M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q1'25+107%
$0.95
Q2'25+124%
$1.23
Q3'25-129%
$-0.16
Q4'25-134%
$-0.22
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+12.87%

Compounded Profit Growth

10 Years:—
5 Years:-50.11%
3 Years:-42.85%
TTM:-18.18%

Stock Price CAGR

10 Years:-2.78%
5 Years:-4.85%
3 Years:-14.74%
1 Year:-13.25%

Return on Equity

10Y Avg:0.5%
5Y Avg:2.7%
3Y Avg:4.0%
Last Year:5.7%

Key Metrics

Market Cap$11.9B
Gross Margin77.1%
Net Margin10.8%
Piotroski F-Score5/9

More BMRN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

BMRN vs AGIOAGIOVRTXASNDBBIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 60 meansBMRN outperformed 60% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.74 means 26% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with WARM status.

Frequently Asked Questions

Is BMRN in an uptrend right now?

BMRN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is BMRN overbought or oversold?

BMRN's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.

Is BMRN outperforming the market?

BMRN has a Relative Strength (RS) Rating of 60 out of 99. BMRN is performing about average compared to the market.

Where is BMRN in its 52-week range?

BMRN is trading at $61.73, which is 84% of its 52-week high ($73.51) and 48% above its 52-week low ($50.76).

How volatile is BMRN?

BMRN has a Beta of 0.74 and 52-week volatility of 35%. It's less volatile than the S&P 500 - generally more stable.